Abcam, a global innovator in life science reagents and tools, and MEDx Translational Medicine (MEDx), formerly Qiagen (Suzhou) Translational Medicine, a company dedicated to developing companion diagnostics and precision medicine, announced the extension of their strategic partnership to include the co-development and commercialization of key companion and in vitro diagnostic kits for MEDx to supply to the Chinese market.
Nick Zhang, CEO of MEDx commented: “China is embracing the arrival of precision medicine, creating unprecedented opportunities for the pharma and healthcare industry. This new collaboration expands our strong relationship with Abcam and leverages their integrated solutions to support the development of innovative diagnostic kits from target validation to clinical trial testing.”
Under the terms of the agreement, the partners will together define target product profiles that will support the growth of precision diagnostic for selected indications in China. Abcam will provide MEDx with access to the corresponding validated specific antibodies from their pipeline and portfolio and will co-create novel binders as required. MEDx will complete the development of these into companion diagnostics and in vitro diagnostic kits for wider commercialization.
Dr John Baker, SVP of business development at Abcam said: “We are looking forward to combining our end-to-end capabilities to identify and develop high-quality recombinant monoclonal antibodies with MEDx’s companion diagnostics development experience. We are excited to be partnering with MEDx and supporting their commitment to accelerate the development and marketing of precision medicine that can positively impact people’s lives across China.”
This agreement builds on an existing collaboration formed in 2018, which has delivered antibody solutions designed specifically to support the development and commercialization of several in vitro diagnostic reagents and kits by MEDx that address key targets, including NY-ESO-1, Claudin 18.2, HER2, Trop2, LAG-3 and CD73.
